The final details of the decree may differ from those detailed above, making the precise nature of t...
Read moreThis study investigates how gaps in the current evidence are linked to access restrictions and mitig...
Read moreIn this study, we compared the use of financial agreements for oncology and non-oncology drugs asses...
Read moreThis study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...
Read moreDetermine the potential price and reimbursement status of a prospective business development asset.
Read moreSince 29 July 2016 NICE) has employed a new fast-track appraisal process for oncology drugs.
Read moreBiosimilars are becoming more widely available across Europe, with many payers at each level involve...
Read moreThis research highlights the variability regarding the scientific advice submission processes and sc...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreThis study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...
Read more